Many checkpoint inhibitors directed at the PD‐1/PD‐L1 pathway have been developed to treat various cancers, such as head and neck cancer, NSCLC, urothelial carcinoma, renal cell carcinoma, and melanoma. This evidence concerns the gene CD274 and cancer.